iTeos Therapeutics Deprioritizes Inupadenant Despite Encouraging Phase 2 Data in NSCLC

Deprioritization Decision:
iTeos Therapeutics has decided to deprioritize the development of inupadenant, an adenosine A2A receptor antagonist, due to insufficient clinical activity despite encouraging Phase 2 data in metastatic non-small cell lung cancer (NSCLC) patients135.

Phase 2 Data:
The Phase 2 A2A-005 trial showed a 63.9% overall response rate (ORR) and a median progression-free survival (PFS) of 7.7 months for all evaluable patients across the cohorts when inupadenant was combined with carboplatin and pemetrexed15.

Reason for Deprioritization:
Despite the positive data, iTeos believes that inupadenant does not meet the sufficient level of clinical activity to warrant further investment, leading to the decision to focus resources on other programs135.

Future Plans:
iTeos plans to provide more details about its pipeline in 2025, indicating a shift in focus towards other differentiated, first- or best-in-class therapies13.

Adenosine Signature:
The company also presented data on an adenosine signature, which could be a powerful tool for prioritizing tumor types that may benefit most from adenosine-targeting therapies and understanding adenosine-mediated immunosuppression15.

Sources:

1. https://investors.iteostherapeutics.com/news-releases/news-release-details/iteos-therapeutics-presents-interim-a2a-005-clinical-trial-data

3. https://www.biospace.com/drug-development/cancer-pipelines-shrink-as-incyte-iteos-cut-candidates-following-disappointing-data

5. https://www.globenewswire.com/news-release/2024/12/12/2996233/0/en/iTeos-Therapeutics-Presents-Interim-A2A-005-Clinical-Trial-Data-Translational-and-Preclinical-Data-from-Inupadenant-at-ESMO-Immuno-Oncology-Congress.html